Linkedin
Facebook
Twitter
Youtube

Agenda

View the 2023 Agenda!

The 2023 Cell & Gene Meeting on the Med will be delivered in a hybrid format with live programming available over the course of two days at the Hotel Arts Barcelona. Virtual registrants will have access to all content via livestream during the program dates. Additionally, all content will be made available on-demand within 24 hours of the live program time for all registrants to view.

Quick Links

REGISTRATION
SPONSORS
COMPANY PRESENTERS

Agenda Sponsors:

2023 Meeting Agenda

  • Full Agenda

7:30am – 9:00am | REGISTRATION

Sponsored by Akron Biotech

8:00am | PARTNERING OPENS

9:00am | GENERAL SESSION

WELCOME REMARKS
{BioCentriq Ballroom}

9:00am – 9:15am

Speakers:

Tim Hunt, CEO, Alliance for Regenerative Medicine (ARM)

Devyn Smith, Ph.D., CEO, Arbor Biotechnologies; Chairman, Alliance for Regenerative Medicine (ARM)

9:15am – 10:15am | CONCURRENT TRACKS

PLENARY SESSION: A NEW ERA FOR ATMPS – COMMERCIALIZING IN THE EU
{BioCentriq Ballroom}

9:15am – 10:15am
Executives from companies with experience commercializing cell and gene therapies in the European Union will describe the current landscape and lessons learned. What are the trends among payers and HTA bodies? What has led to success in establishing patient access? What are the main barriers and opportunities to commercialization in the EU?

Chair:

Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult

Speakers:

Lutz Bonacker, Ph.D., Senior Vice President and General Manager, Commercial Operations Europe, CSL Behring

Emmanuel Chantelot, Vice President, Head of International Policy and Government Affairs, Bristol-Myers Squibb

Chris Fox, President, Novartis Gene Therapies

COMPANY PRESENTATIONS
{Dark Horse Consulting Ballroom}

9:15am – 10:15am

9:15am – 9:30amCryoport Systems
9:30am – 9:45amRay Therapeutics
9:45am – 10:00amExothera
10:00am – 10:15amRoslinCT

10:15am – 10:45am | MORNING BREAK

Sponsored by Anocca

10:45am – 12:30pm | CONCURRENT TRACKS

COMPANY PRESENTATIONS

{BioCentriq Ballroom}

10:45am – 11:00amIN8bio
11:00am – 11:15amAutolus Therapeutics
11:15am – 11:30amPrescient Therapeutics
11:30am – 11:45amVor Bio
11:45am – 12:00pmPDC*line Pharma
12:00pm – 12:15pmOrchard Therapeutics
12:15pm – 12:30pmCabaletta Bio

COMPANY PRESENTATIONS

{Dark Horse Consulting Ballroom}

10:45am – 11:00amAffyXell Therapeutics
11:00am – 11:15amKiji Therapeutics
11:15am – 11:30amQuell Therapeutics
11:30am – 11:45amResolution Therapeutics
11:45am – 12:00pmArbor Biotechnologies
12:00pm – 12:15pmAspect Biosystems
12:15pm – 12:30pmForm Bio

12:30pm – 1:45pm | LUNCH

Sponsored by Notch Therapeutics

1:45pm – 3:15pm | CONCURRENT TRACKS

THE HOSPITAL EXEMPTION: A NECESSARY SHORTCUT OR THE END OF HIGH REGULATORY STANDARDS?
{BioCentriq Ballroom}

1:45pm – 2:45pm

Chair:

Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics

Speakers:

Gonzalo Calvo Rojas, M.D., Ph.D., Head, Clinical Pharmacology Department and Coordinator of Advanced Therapies, Hospital Clinic of Barcelona

Paschalia Koufokotsiou, Policy Officer, Pharmaceutical and Health Policy, DG SANTE, European Commission

Christopher Vann, Senior Vice President and Chief Operating Officer, Autolus Therapeutics

COMPANY PRESENTATIONS

{Dark Horse Consulting Ballroom}

1:45pm – 2:00pmForge Biologics
2:00pm – 2:15pmAffini-T Therapeutics
2:15pm – 2:30pmNKILT Therapeutics
2:30pm – 2:45pmNotch Therapeutics

SPOTLIGHT SESSION: THE FUTURE OF MRNA FOR CELL AND GENE THERAPIES
{BioCentriq Ballroom}

2:45pm – 3:15pm

Speaker:

Paolo Martini, Ph.D., Chief Scientific Officer International Therapeutics Research Centers; Founder, Moderna Rare Diseases, Moderna

COMPANY PRESENTATIONS

{Dark Horse Consulting Ballroom}

2:45pm – 3:00pmAvectas
3:00pm – 3:15pmAndelyn Biosciences

3:15pm – 3:45pm | AFTERNOON BREAK

Sponsored by Anocca

3:45pm – 5:30pm | CONCURRENT TRACKS

ROI: WHAT INVESTORS WANT TO SEE IN THE EUROPEAN ATMP ECOSYSTEM

{BioCentriq Ballroom}

3:45pm – 4:45pm

Chair:

Phil Vanek, Ph.D., Chief Technology Officer and Partner, Gamma Biosciences

Speakers:

Geoffroy de Ribains, Managing Partner, AdBio partners

Lucia Faccio, Ph.D., Partner, Sofinnova Partners

Edward Hodgkin, Ph.D., Senior Partner, Syncona Investment Management; CEO, Resolution Therapeutics

Jordi Xiol, Ph.D., Partner, Ysios Capital

COMPANY PRESENTATIONS

{Dark Horse Consulting Ballroom}

3:45pm – 4:00pmTrakCel
4:00pm – 4:15pmL7 Informatics
4:15pm – 4:30pmPeterBio
4:30pm – 4:45pmTreeFrog Therapeutics

EXTRAORDINARY SCIENCE: NAVIGATING CGTX DEVELOPMENT IN 2023 WORKSHOP

Sponsored by Precision ADVANCE
{BioCentriq Ballroom}

4:45pm – 5:30pm
This panel will feature insights from industry leaders on the future of advanced medicines including:

  • Market trends and expectations for CGTx in 2023
  • Predictions on potential approvals in 2023
  • Innovative trends and technologies
  • Pricing, reimbursement, and value demonstration
  • Evolution of CMC and manufacturing

Chair:

Anshul Mangal, President, Project Farma and Precision ADVANCE

Speakers:

Phil Cyr, Senior Vice President, Precision Value & Health

Bobby Gaspar, M.D., Ph.D., CEO, Orchard Therapeutics

Kim Nguyen, Ph.D., Chief Technical Officer, Affini-T Therapeutics

Devyn Smith, Ph.D., CEO, Arbor Biotechnologies; Chairman, Alliance for Regenerative Medicine (ARM)

Philip Toleikis, Ph.D., President and CEO, Sernova Corp

TRANSFORMING THE WILD FRONTIER – INDUSTRIALIZATION OF ADVANCED THERAPIES WORKSHOP

Sponsored by Charles River Laboratories

{Dark Horse Consulting Ballroom}

4:45pm – 5:30pm
As the cell and gene therapy field transitions from the wild frontier into the industrial age, one of the key challenges ahead will be how to scale a therapeutic candidate efficiently and cost-effectively to meet patient population demand. This session will discuss insights from evaluating new technologies, to their implementation, and moving to high throughput manufacturing for taking advanced therapies from the clinic to the market.

Chair:

Matthew Hewitt, Ph.D., Vice President, Technical Officer Cell and Gene Therapy and Biologics, Charles River Laboratories

Speakers:

Lisa Deschamps, CEO and Executive Board Member, AviadoBio

Pedro Gonzalez-Alegre, M.D., Ph.D., Head of Gene Therapy Research, Spark Therapeutics

John Hadden, CEO and Co-founder, ViroCell Biologics

Sven Kili, M.D., CEO and Board Member, Antion Biosciences

5:30pm | PROGRAM AND PARTNERING CLOSES

5:30pm – 8:30pm | NETWORKING BASH

Sponsored by Bio-Techne and ScaleReady

7:30am – 9:00am | REGISTRATION

Sponsored by Akron Biotech

8:00am | PARTNERING OPENS

9:00am | GENERAL SESSION

CLOSING REMARKS

{BioCentriq Ballroom}

9:00am – 9:15am

Speaker:

Tim Hunt, CEO, Alliance for Regenerative Medicine (ARM)

9:15am – 10:15am | CONCURRENT TRACKS

HOPES AND CONCERNS: HOW PATIENTS AND CAREGIVERS APPROACH ATMPS
{BioCentriq Ballroom}

9:15am – 10:15am

Cell and gene therapies represent hope for patients with few, or no, treatment options. But patients and their caregivers also have questions, and sometimes concerns, about how the therapies work, what the risks are, and the commitment required to undergo treatment. Prominent representatives from the patient community will share perspectives on how patients approach ATMPs.

Chair:

Bob Smith, Senior Vice President, Global Gene Therapy Business, Pfizer

Speakers:

Matt Bolz-Johnson, Mental Health Lead and Healthcare Advisor, EURORDIS

Brian O’Mahony, Chief Executive, Irish Haemophilia Society

Christos Sotirelis, Ph.D., International Relations Lead, Comitato Famiglie Talassemici (CFT) Florence

Durhane Wong-Rieger, Ph.D., Board Chair, Rare Diseases International

COMPANY PRESENTATIONS

{Dark Horse Consulting Ballroom}

9:15am – 9:30amAldevron
9:30am – 9:45amEG 427
9:45am – 10:00amSpirovant
10:00am – 10:15amCTI

10:15am – 10:30am | MORNING BREAK

Sponsored by Anocca

10:30am – 12:30pm | CONCURRENT TRACKS

LEADER’S FORUM ON EU HEALTH TECHNOLOGY ASSESSMENT FOR ATMPS

{BioCentriq Ballroom}

10:30am – 11:30am
The European HTA Regulation has introduced an EU-level Joint Clinical Assessment of the benefits of ATMPs, to inform national reimbursement decisions. The requirements and expectations that will form the basis for these assessments will have far-reaching impact on patient access to these treatments. This session will examine the objectives and implications of Joint Clinical Assessment from the perspectives of the Commission, developers and HTAs, and discuss the conditions for a workable system.

Chair:

Nicholas Gertler, Co-Founder, Galen/Atlantica

Speakers:

François Houÿez, Information and Access to Therapies Director and Health Policy Advisor, EURORDIS

Carole Longson, Vice Chair, Medicines Discovery Catapult; Former Executive Director, NICE

Marco Marchetti, M.D., Head, HTA Agenas Italy; Co-chair, EU HTA Coordination Group

Francis Pang, Senior Vice President, Global Market Access and Geographic Expansion, Orchard Therapeutics

COMPANY PRESENTATIONS

{Dark Horse Consulting Ballroom}

10:30am – 10:45amCellistic
10:45am – 11:00amCarisma Therapeutics
11:00am – 11:15amLuminary Therapeutics
11:15am – 11:30amAntion Biosciences

COMPANY PRESENTATIONS

{BioCentriq Ballroom}

11:30am – 11:45amXintela
11:45am – 12:00pmNovo Nordisk
12:00pm – 12:15pmCynata Therapeutics
12:15pm – 12:30pmGENETHON

COMPANY PRESENTATIONS

{Dark Horse Consulting Ballroom}

11:30am – 11:45amAnocca
11:45am – 12:00pmElevateBio
12:00pm – 12:15pmSaxoCell – Fraunhofer IZI
12:15pm – 12:30pmEmendo Biotherapeutics

12:30pm – 1:30pm | LUNCH

Sponsored by Dark Horse Consulting

1:30pm – 3:00pm | CONCURRENT TRACKS

COMPANY PRESENTATIONS

{BioCentriq Ballroom}

1:30pm – 1:45pmCoave Therapeutics
1:45pm – 2:00pmOxford Biomedica

COMPANY PRESENTATIONS

{Dark Horse Consulting Ballroom}

1:30pm – 1:45pmAccelerated Biosciences
1:45pm – 2:00pmMaxCyte

THE PIONEER’S TAX: CHALLENGES AND OPPORTUNITIES OF BEING AT THE FOREFRONT OF INNOVATION

{BioCentriq Ballroom}

2:00pm – 3:00pm
In any industry, significant challenges exist to pioneers who bring forward new and highly disruptive technology. Our panel will explore this topic for cutting edge gene and cell therapies.

Chair:

Jeff Ross, Ph.D., CEO, Miromatrix Medical

Speakers:

Andrew Bellinger, M.D., Ph.D., Chief Scientific Officer and Chief Medical Officer, Verve Therapeutics

Seth Ettenberg, Ph.D., President and CEO, BlueRock Therapeutics

Tracey Lodie, Ph.D., Chief Scientific Officer, Quell Therapeutics

Johanna Rossell, Chief Commercial Officer, Enzyvant Therapeutics

Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer, Intellia Therapeutics

COMPANY PRESENTATIONS

{Dark Horse Consulting Ballroom}

2:00pm – 2:15pmAviadoBio
2:15pm – 2:30pmDyno Therapeutics
2:30pm – 2:45pmLife Edit Therapeutics
2:45pm – 3:00pmNanite

3:00pm – 3:15pm | AFTERNOON BREAK

Sponsored by Anocca

3:15pm – 5:00pm | CONCURRENT TRACKS

COMPANY PRESENTATIONS

{BioCentriq Ballroom}

3:15pm – 3:30pmUnicyte
3:30pm – 3:45pmMiromatrix
3:45pm – 4:00pmSernova

COMPANY PRESENTATIONS

{Dark Horse Consulting Ballroom}

3:15pm – 3:30pmVectorY Therapeutics
3:30pm – 3:45pmVERIGRAFT
3:45pm – 4:00pmGlycostem Therapeutics

PLANNING FOR CGT COMMERCIAL READINESS: ADAPTIVE MANUFACTURING STRATEGY

{BioCentriq Ballroom}

4:00pm – 5:00pm

In the dynamic environment of the cell and gene therapy space, ensuring future commercial success involves flexibility in decision making during the planning for commercial scale-up. This expert panel will discuss adaptive manufacturing strategy through every stage of development, from building predictive scale-down models, to investment in technological innovation, data analytics, and automation.

Chair:

John Maslowski, Chief Commercial Officer, Forge Biologics

Speakers:

Øystein Åmellem, Ph.D., Director, Cell Therapy, Thermo Fisher Scientific

Robert Ang, President and CEO, Vor Bio

Barbara Sanders, Ph.D., Chief Technology Officer, VectorY Therapeutics

Alberto Santagostino, Senior Vice President, Head of Cell and Gene Technologies, Lonza

COMPANY PRESENTATIONS

{Dark Horse Consulting Ballroom}

4:00pm – 4:15pmAtamyo Therapeutics
4:15pm – 4:30pmCEVEC
4:30pm – 4:45pmSNBTS
4:45pm – 5:00pmMekonos

5:00pm | PROGRAM AND PARTNERING CLOSES

5:00pm – 7:00pm | WINE TASTING RECEPTION

Sponsored by Oxford Biomedica

8:30am – 12:00pm | ARM EU COMMITTEE MEETINGS

Open to ARM Members Only

EUROPEAN ADVISORY COMMITTEE
{Granados}

8:30am – 10:00am

EUROPEAN REGULATORY AFFAIRS WORKSHOP
{Granados}

10:00am – 12:00pm

 

 

 

EUROPEAN MARKET ACCESS AND VALUE COMMITTEE
{Clavé}

10:00am – 11:00am

About the Event

The Cell & Gene Meeting on the Mediterranean is the leading conference bringing together the ATMP community from Europe and beyond. Covering a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector, this program features expert-led panels, extensive one-on-one partnering capabilities, exclusive networking opportunities, and 60+ dedicated presentations by leading publicly traded and privately held companies in the space. Join ARM for Europe’s premier conference for advanced therapies.

Dates & Location

April 12-14, 2023
Hotel Arts Barcelona
Marina 19-21
Barcelona, Spain

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions